A Phase 1, Randomized, Open-Label Study of the Relative Bioavailability and Effect of Food on the Pharmacokinetics of a Novel Formulation of PRN2246 Compared to a Reference Formulation in Healthy Adult Participants
Phase of Trial: Phase I
Latest Information Update: 22 Mar 2019
Price : $35 *
At a glance
- Drugs PRN-2246 (Primary)
- Indications Multiple sclerosis
- Focus Pharmacokinetics
- Sponsors Principia Biopharma
- 23 Jan 2019 Status changed from recruiting to completed.
- 22 Oct 2018 Status changed from not yet recruiting to recruiting.
- 18 Sep 2018 New trial record